Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

"Once-yearly intramuscular lenacapavir for HIV PrEP has the potential to improve PrEP uptake and persistence and thus improve the scalability and public health impact of PrEP in populations who ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...